Potential new treatment for HIV could mean dosing patients only once a year

Written by Lucy Chard, Editor

HIV nanocrystal prodrug annual treatment

A research team from the University of Nebraska Medical Center (UNMC; NE, USA) led by Benson Edagwa (Assistant Professor) and Howard Gendelman (Chairman and Professor) have developed a potential novel therapeutic for the prevention of HIV infection. The team have discovered a way to administer antiretrovirals (ARVs) that patients take daily to control the disease, to just a once-a-year vaccine dose instead. “This pharmaceutical development has the potential to not only treat but also prevent viral transmission,” stated Gendelman. “This may certainly be a therapeutic milestone.” The year-long acting drug is based on the existing drug cabotegravir (CAB), which blocks...

To view this content, please register now for access

It's completely free